YusukeSuzuki TokyoJapan

• What makes IgA pathogenic in IgA nephropathy?
  YusukeSuzuki Speaker yusuke@juntendo.ac.jpJapan
• The role of B Cells in IgA nephropathy
  HeatherReich Speaker Heather.Reich@uhn.caCanada
• Targeting pathogenic IgA in IgA nephropathy
  Jonathan Barratt Speaker jb81@leicester.ac.ukUnited Kingdom

• Exploring the Role of APRIL in IgA Nephropathy: Pathogenesis to Progression
  Chee KayCheung Speaker ckc15@leicester.ac.ukUnited Kingdom

  HeatherReich Speaker Heather.Reich@uhn.caCanada

• Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist)
  HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
• Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial
  XiaobingYang Speaker yxb7829@163.comChina
• Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy (IgAN): Final 24-month Results From the Phase III APPLAUSE-IgAN Study
  VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia
• Q&A

• Evolving Landscape of IgA Nephropathy in 2026 and Beyond
  HongZhang Speaker hongzh@bjmu.edu.cnChina

• Welcome and introduction
  YusukeSuzuki Speaker yusuke@juntendo.ac.jpJapan
• Audience pooling
  Chee KayCheung Speaker ckc15@leicester.ac.ukUnited Kingdom
• Recent guidelines updates in IgAN-The rationale
  Chee KayCheung Speaker ckc15@leicester.ac.ukUnited Kingdom
• The old and the new to approaching treatment
  SaynaNorouzi Speaker sayna.nrz@gmail.comUnited States
• Summary and close
  YusukeSuzuki Speaker yusuke@juntendo.ac.jpJapan